免疫检查点抑制剂用于晚期肺癌伴致癌驱动基因改变患者:IMMUNOTARGET登记研究结果
该回顾性研究纳入10个国家24个中心551例接受ICI单药治疗的晚期NSCLC伴至少一种致癌驱动基因改变患者,评估疗效。各驱动基因客观缓解率:KRAS 26%、BRAF 24%、ROS1 17%、MET 16%、EGFR 12%、HER2 7%、RET 6%、ALK 0%。全队列中位PFS 2.8个月,OS 13.3个月,最佳缓解率19%。
要点
- ICI在部分驱动基因改变肿瘤中可诱导缓解,但活性低于KRAS组,ALK组无缓解值得注意。
- 作者建议:有可用靶向改变的患者应先接受靶向治疗和化疗,再考虑单药免疫治疗。
- 部分亚组中PFS与PD-L1表达(KRAS、EGFR)及吸烟状态(BRAF、HER2)呈正相关。
核心结论
- ICI在部分具有可操作驱动基因改变的肿瘤中诱导缓解,但临床活性低于KRAS组,ALK组无缓解值得注意。
- 作者认为,具有可操作肿瘤改变的患者应先接受靶向治疗和化疗,再考虑单药免疫治疗。
研究设计与样本
- 回顾性研究,纳入接受ICI单药治疗的晚期NSCLC且至少有一种致癌驱动基因改变的患者。
- 共分析551例患者,来自10个国家的24个中心。
- 主要终点为ICI治疗下的PFS,次要终点为最佳缓解(RECIST 1.1)和自ICI开始计算的OS。
主要发现
- 分子改变涉及KRAS(n=271)、EGFR(n=125)、BRAF(n=43)、MET(n=36)、HER2(n=29)、ALK(n=23)、RET(n=16)、ROS1(n=7)和多驱动基因(n=1)。
- 中位年龄60岁,性别比1:1,从不/既往/当前吸烟者分别为28%/51%/21%,大多数肿瘤为腺癌。
- 各驱动基因客观缓解率:KRAS 26%、BRAF 24%、ROS1 17%、MET 16%、EGFR 12%、HER2 7%、RET 6%、ALK 0%。
- 全队列中位PFS 2.8个月,OS 13.3个月,最佳缓解率19%。
- 亚组分析中位PFS(月):EGFR 2.1、KRAS 3.2、ALK 2.5、BRAF 3.1、HER2 2.5、RET 2.1、MET 3.4;部分亚组PFS与PD-L1表达(KRAS、EGFR)及吸烟状态(BRAF、HER2)呈正相关。
关键数值与推荐
- 各驱动基因客观缓解率:KRAS 26%、BRAF 24%、ROS1 17%、MET 16%、EGFR 12%、HER2 7%、RET 6%、ALK 0%。
- 全队列中位PFS 2.8个月,OS 13.3个月,最佳缓解率19%。
- 亚组中位PFS(月):EGFR 2.1、KRAS 3.2、ALK 2.5、BRAF 3.1、HER2 2.5、RET 2.1、MET 3.4。
临床怎么用
- 作者认为,具有可操作肿瘤改变的患者应先接受靶向治疗和化疗,再考虑单药免疫治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction. PATIENTS AND METHODS: We conducted a retrospective study for patients receiving ICI monotherapy for advanced NSCLC with at least one oncogenic driver alteration. Anonymized data were evaluated for clinicopathologic characteristics and outcomes for ICI therapy: best response (RECIST 1.1), progression-free survival (PFS), and overall survival (OS) from ICI initiation. The primary end point was PFS under ICI. Secondary end points were best response (RECIST 1.1) and OS from ICI initiation. RESULTS: We studied 551 patients treated in 24 centers from 10 countries. The molecular alterations involved KRAS (n = 271), EGFR (n = 125), BRAF (n = 43), MET (n = 36), HER2 (n = 29), ALK (n = 23), RET (n = 16), ROS1 (n = 7), and multiple drivers (n = 1). Median age was 60 years, gender ratio was 1 : 1, never/former/current smokers were 28%/51%/21%, respectively, and the majority of tumors were adenocarcinoma. The objective response rate by driver alteration was: KRAS = 26%, BRAF = 24%, ROS1 = 17%, MET = 16%, EGFR = 12%, HER2 = 7%, RET = 6%, and ALK = 0%. In the entire cohort, median PFS was 2.8 months, OS 13.3 months, and the best response rate 19%. In a subgroup analysis, median PFS (in months) was 2.1 for EGFR, 3.2 for KRAS, 2.5 for ALK, 3.1 for BRAF, 2.5 for HER2, 2.1 for RET, and 3.4 for MET. In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2). CONCLUSIONS: : ICI induced regression in some tumors with actionable driver alterations, but clinical activity was lower compared with the KRAS group and the lack of response in the ALK group was notable. Patients with actionable tumor alterations should receive targeted therapies and chemotherapy before considering immunotherapy as a single agent.
引用
- Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019. PMID: 31125062. doi:10.1093/annonc/mdz167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。